Register

Mayo Clinic   

Questions discussed in this category

How do you approach treatment for a patient with a biochemical relapse while on maintenance lenalidomide after autologous stem cell transplant for multiple myeloma?
What factors (i.e. timing from transplant, dose, prior therapy) impact your decision? 
1 Answer available
What factors do you look at while deciding between a daratumumab-based quadruplet induction versus standard triplet induction such as VRd for newly diagnosed MM?
1 Answer available
How do you now approach treatment sequencing in MM in light of the DETERMINATION trial data?
Do the results change your clinical practice?
2 Answers available
How do you approach the decision to pursue early versus delayed autologous stem cell transplantation in newly diagnosed multiple myeloma?
1 Answer available
What is your experience with using Frailty Index or other geriatric screening in making decisions for elderly patients with multiple myeloma?
Frailty Index per Palumbo et al. PMID 25628469Is it practical to apply in clinics? Have you made decision changes based on it?
2 Answers available
What is your treatment of choice for triple class refractory multiple myeloma?
CAR-T (any specific preference of product?) vs bispecific antibodies vs any other specific agents not previously utilized?
2 Answers available
Do you prefer carboplatin or cisplatin with etoposide for stage IV extra-pulmonary neuroendocrine carcinomas with a Ki-67 > 55%?
1 Answer available
What is your preferred maintenance strategy for high risk multiple myeloma?
2 Answers available
Would you consider PRRT re-treatment in a patient with a well differentiated NET previously treated with 4 cycles of PRRT?
2 Answers available
What is the role of liver transplant in NET?
3 Answers available


Papers discussed in this category

Am J Transplant, 2016 Jun 09
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors.
Transplantation, 2021 Apr 27
Postrecurrence Survival After Liver Transplantation for Liver Metastases From Neuroendocrine Tumors.
Surgery, 2017 Jun 16
Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.
JAMA Oncol, 2020 Apr 16
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
Eur J Nucl Med Mol Imaging, 2018 Sep 28
Salvage peptide receptor radionuclide therapy with [Lu-DOTA,Tyr]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours.
Br J Radiol, 2018 Mar 20
Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response.
Eur J Nucl Med Mol Imaging, 2013 Sep 13
Outcome and toxicity of salvage therapy with 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours.
BMC Cancer, 2019 Aug 08
Salvage PRRT with Lu-DOTA-octreotate in extensively pretreated patients with metastatic neuroendocrine tumor (NET): dosimetry, toxicity, efficacy, and survival.
Scand J Gastroenterol, 2021 Jan 20
Clinical efficacy of first and second series of peptide receptor radionuclide therapy in patients with neuroendocrine neoplasm: a cohort study.
Int J Endocrinol, 2021 Jan 23
The Safety and Efficacy of the Repeated PRRT with [Y]Y/[Lu]Lu-DOTATATE in Patients with NET.
Cancer Treat Rev, 2020 Dec 22
Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
The New England journal of medicine, 2012-05-10
Lenalidomide after stem-cell transplantation for multiple myeloma.
Nature communications, 2019-04-23
Multiple myeloma immunoglobulin lambda translocations portend poor prognosis.
Blood, 2012 Aug 13
Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial.
J Clin Oncol, 2020 Apr 16
Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma.
Blood,
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-10-10
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
The New England journal of medicine, 2017-04-06
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
The Lancet. Oncology, 2019-01
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Blood,
Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
Lancet, 2019 Jun 03
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Blood,
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood, 2015-03-26
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Clin Lymphoma Myeloma Leuk, 2019 Oct 09
Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma.
JCO Oncol Pract, 2019 Nov 25
Integrating Touchscreen-Based Geriatric Assessment and Frailty Screening for Adults With Multiple Myeloma to Drive Personalized Treatment Decisions.
The New England journal of medicine, 2019-05-30
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
N Engl J Med, 2022 Jun 05
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Related Topics

Copyright © 2025 theMednet
All Rights Reserved.